Sanjiv J Shah

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. Patel R, Shah S. Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. Annu Rev Pharmacol Toxicol. 2019;59:41-63 pubmed publisher
    ..In this review, we aim to discuss novel pharmacotherapies for HFpEF based on its unique pathophysiology and identify key research strategies to further elucidate mechanistic pathways to develop novel therapeutics in the future. ..
  2. Shah S, Katz D, Selvaraj S, Burke M, Yancy C, Gheorghiade M, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131:269-79 pubmed publisher
    ..Statistical learning algorithms applied to dense phenotypic data may allow improved classification of heterogeneous clinical syndromes, with the ultimate goal of defining therapeutically homogeneous patient subclasses. ..
  3. Silverman D, Shah S. Treatment of Heart Failure With Preserved Ejection Fraction (HFpEF): the Phenotype-Guided Approach. Curr Treat Options Cardiovasc Med. 2019;21:20 pubmed publisher
    ..Here, we review a "phenotype-guided" approach to the management of patients with HFpEF, based on a stepwise method of making the HFpEF diagnosis, identifying the prominent sources of organ dysfunction, and treating accordingly. ..
  4. Lane Cordova A, Khan S, Grobman W, Greenland P, Shah S. Long-Term Cardiovascular Risks Associated With Adverse Pregnancy Outcomes: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73:2106-2116 pubmed publisher
    ..Understanding the risk factors for and pathogenesis of APO-related cardiovascular dysfunction is a critical unmet need that could inform efforts to prevent and more effectively treat CVD in women. ..
  5. Burns J, Sanchez C, Beussink L, Daruwalla V, Freed B, Selvaraj S, et al. Lack of Association Between Anemia and Intrinsic Left Ventricular Diastolic Function or Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2018;122:1359-1365 pubmed publisher
    ..50 [95% confidence interval 1.20, 1.88]; p < 0.001). In conclusion, anemia in HFpEF is associated with markers of volume status and not intrinsic markers of myocardial dysfunction. ..
  6. Khan S, Kim K, Peng J, Aguilar F, Selvaraj S, Martinez E, et al. Clinical correlates and heritability of cardiac mechanics: The HyperGEN study. Int J Cardiol. 2019;274:208-213 pubmed publisher
    ..These findings provide the basis for future studies of genetic determinants of these traits that may elucidate race-based differences in heart failure development. ..
  7. Selvaraj S, Aguilar F, Martinez E, Beussink L, Kim K, Peng J, et al. Diastolic wall strain: a simple marker of abnormal cardiac mechanics. Cardiovasc Ultrasound. 2014;12:40 pubmed publisher
    ..79, and 0.84, respectively. DWS, a simple parameter than can be calculated from routine 2D echocardiography, is closely associated with systolic strain parameters and early diastolic (e') tissue velocities but not LV chamber compliance. ..
  8. Klein D, Katz D, Beussink Nelson L, Sanchez C, Strzelczyk T, Shah S. Association of Chronic Kidney Disease With Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2015;116:1093-100 pubmed publisher
    ..In conclusion, reduced GFR is the major clinical correlate of CI in patients with HFpEF, and further study of the relation between chronic kidney disease and CI may provide insight into the pathophysiology of CI in HFpEF. ..
  9. Katz D, Burns J, Aguilar F, Beussink L, Shah S. Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction. JACC Heart Fail. 2014;2:586-96 pubmed publisher
    ..In HFpEF, increased UACR is a prognostic marker and is associated with increased RV and left ventricular remodeling and longitudinal systolic dysfunction. (Classification of Heart Failure With Preserved Ejection Fraction; NCT01030991). ..

More Information

Publications26

  1. Mitter S, Shah S. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?. Curr Atheroscler Rep. 2015;17:64 pubmed publisher
  2. Dixon D, Trivedi A, Shah S. Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Heart Fail Rev. 2016;21:285-97 pubmed publisher
    ..CpcPH-HFpEF is a distinct subset within HFpEF and one that may respond to targeted therapeutics. ..
  3. Raphael R, Purushotham D, Gastonguay C, Chesnik M, Kwok W, Wu H, et al. Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction. J Transl Med. 2016;14:18 pubmed publisher
    ..S100A8 has been linked with other cardiovascular disease such as atherosclerosis and risk for myocardial infarction, stroke, or death. This is the first report on association of S100A8 with HFpEF. ..
  4. Freed B, Daruwalla V, Cheng J, Aguilar F, Beussink L, Choi A, et al. Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction: Importance of Left Atrial Strain. Circ Cardiovasc Imaging. 2016;9: pubmed publisher
    ..Unloading the LA and augmentation of LA function may be important future therapeutic targets in HFpEF. URL: http://www.clinicaltrials.gov. Unique identifier: NCT01030991. ..
  5. Shah S, Blair J, Filippatos G, Macarie C, Ruzyllo W, Korewicki J, et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial. Am Heart J. 2009;157:1035-41 pubmed publisher
    ..047), after controlling for age, sex, baseline ejection fraction, change in PCWP, and change in SBP. Istaroxime decreases PCWP, increases SBP, and decreases diastolic stiffness in patients with acute heart failure syndrome. ..
  6. request reprint
    Shah S, Cogswell R, Ryan J, Sharma K. How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program. Curr Cardiol Rep. 2016;18:122 pubmed
    ..It is our hope that the information provided here will encourage others to establish their own specialized HFpEF programs, thereby allowing for comprehensive care for these complex patients. ..
  7. Selvaraj S, Martinez E, Aguilar F, Kim K, Peng J, Sha J, et al. Association of Central Adiposity With Adverse Cardiac Mechanics: Findings From the Hypertension Genetic Epidemiology Network Study. Circ Cardiovasc Imaging. 2016;9: pubmed publisher
    ..There were no significant statistical interactions between WHR and obesity status. In this cross-sectional study of participants with multiple comorbidities, central obesity was found to be associated with adverse cardiac mechanics. ..
  8. Freed B, Collins J, François C, Barker A, Cuttica M, Chesler N, et al. MR and CT Imaging for the Evaluation of Pulmonary Hypertension. JACC Cardiovasc Imaging. 2016;9:715-32 pubmed publisher
    ..Here we discuss the role of magnetic resonance imaging and computed tomography in the diagnosis and management of PH, including current uses and novel research applications, and we discuss the role of value-based imaging in PH. ..
  9. Shah S, Heitner J, Sweitzer N, Anand I, Kim H, Harty B, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013;6:184-92 pubmed publisher
    ..URL: http://www.clinicaltrials.gov. UNIQUE IDENTIFIER: NCT00094302. ..
  10. Subramanya V, Zhao D, Ouyang P, Lima J, Vaidya D, Ndumele C, et al. Sex hormone levels and change in left ventricular structure among men and post-menopausal women: The Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas. 2018;108:37-44 pubmed publisher
    ..A more androgenic profile (higher free testosterone and lower SHBG levels) is associated with a greater increase in LVM in men and women and greater increase in M:V ratio in women over the course of 9 years. ..
  11. Shah S. Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction. J Cardiovasc Transl Res. 2017;10:322-336 pubmed publisher
    ..Our hope is that the description of the aforementioned innovative trial designs will stimulate new approaches to clinical trials in HFpEF. ..
  12. Polsinelli V, Sinha A, Shah S. Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment. Curr Heart Fail Rep. 2017;14:519-528 pubmed publisher
    ..Modulation of the pathways interconnecting the right heart, visceral congestion, and the intestinal microenvironment could be a novel avenue of intervention for right-sided HF. ..
  13. Feldman T, Mauri L, Kahwash R, Litwin S, Ricciardi M, van der Harst P, et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. Circulation. 2018;137:364-375 pubmed publisher
    ..Whether this mechanistic effect will translate into sustained improvements in symptoms and outcomes requires further evaluation. URL: https://clinicaltrials.gov. Unique identifier: NCT02600234. ..
  14. Katz D, Deo R, Aguilar F, Selvaraj S, Martinez E, Beussink Nelson L, et al. Phenomapping for the Identification of Hypertensive Patients with the Myocardial Substrate for Heart Failure with Preserved Ejection Fraction. J Cardiovasc Transl Res. 2017;10:275-284 pubmed publisher
    ..1 vs. 14.6 ± 3.5%] even after adjustment for traditional comorbidities [p < 0.001]). The 2 hypertension phenogroups may represent distinct subtypes that may benefit from targeted therapies for the prevention of HFpEF. ..
  15. Marangoni R, Korman B, Allanore Y, Dieude P, Armstrong L, Rzhetskaya M, et al. A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis. Arthritis Res Ther. 2015;17:128 pubmed publisher
    ..002; odds ratio=2.33 per C allele, 95% confidence interval 1.34-4.03). A PPARG variant is associated with susceptibility to SSc, consistent with a role of PPAR-γ in the pathogenesis of SSc. ..
  16. Shah S. Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. J Cardiovasc Transl Res. 2017;10:233-244 pubmed publisher
  17. Shah S. Pulmonary hypertension. JAMA. 2012;308:1366-74 pubmed publisher